NCT07110844 - Teclistamab-Daratumumab in AL Amyloidosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 31, 2031

Study Completion Date

October 31, 2033

Conditions

Amyloid Light-chain Amyloidosis

Interventions

DRUG

Teclistamab

Teclistamab is a T-cell redirecting bispecific antibody (BsAb) targeting CD3 on T-cells and B-cell maturation antigen (BCMA) on plasma cells.

DRUG

Daratumumab and Hyaluronidase-fihj

Daratumumab is an monoclonal antibody that targets the CD38 protein on the surface of myeloma cells.

Trial Locations (1)

Columbia University Irving Medical Center, New York